Health · Pharma & Biotech · 23 hrs ago
Biomedical approach to obesity quadruples Galenicum’s value
Galenicum’s value has quadrupled amid a growing biomedical focus on treating obesity.
This approach puts more emphasis on medicines derived from semaglutide as a way to reduce weight.
Semaglutide is the drug named in the debate over this treatment strategy.
Supporters of a biopsychosocial view of medicine say this emphasis is too narrow.
They argue that changes in habits are being left aside in weight-loss strategies.
The disagreement is over how much treatment should focus on medicines and how much on changes in people’s habits.
Galenicum’s value has quadrupled amid a biomedical approach to obesity, according to the story headline.
The approach emphasizes medicines derived from semaglutide as part of a weight-reduction strategy.
Supporters of a biopsychosocial view of medicine criticize this emphasis.
They say it leaves changes in habits aside.
- Who
- Galenicum and supporters of a biopsychosocial view of medicine.
- What
- Galenicum’s value has quadrupled as a biomedical approach to obesity emphasizes medicines derived from semaglutide.
- When
- Not stated.
- Where
- Not stated.
- Why
- The story links the valuation increase to a biomedical approach to obesity; the specific reason for the increase is not stated.
Supporters of a biomedical approach emphasizing semaglutide-derived medicines
Supporters of a biopsychosocial approach to medicine
Approach to weight reduction
Supporters of a biomedical approach emphasizing semaglutide-derived medicines
The strategy emphasizes medicines derived from semaglutide.
Supporters of a biopsychosocial approach to medicine
The strategy should not leave changes in habits aside.
This story does not have a timeline yet.
- Company
- Galenicum
- Valuation change
- Quadrupled
- Medicine focus
- Medicines derived from semaglutide
- Critics
- Defenders of the biopsychosocial view of medicine